Expression and significance of human tissue kallikrein in ovarian cancer

doi:10.3760/cma.j.issn.1673-422X.2014.08.016

Abstract

Abstract: The human tissue kallikrein (KLK) gene family consists of 15 highly conservative serine proteases, which is the largest uninterrupted cluster of protease genes in the human genome. Several members of the family are expected to be markers for tumor diagnosis and prognosis. Studies find that the expressions of KLK2-11 and KLK13-15 are abnormal, and the majority of KLKs have potential diagnostic and prognostic values.

Key words: Ovarian neoplasms, Tumor markers, biological, Human tissue kallikrein

Chu Fangbo, Chen Yingjian, Hu Chengjin. Expression and significance of human tissue kallikrein in ovarian cancer[J]. Journal of International Oncology, 2014, 41(8): 608-611.

References

［1］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1):11-30. ［2］ Dong Y, Stephens C, Walpole C, et al. Paclitaxel resistance and multicellular spheroid formation are induced by kallikreinrelated peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment［J］. PLoS One, 2013, 8(2):e57056. ［3］ Dorn J, Maqdolen V, Gkazepis A, et al. Circulating biomarker tissue kallikreinrelated peptidase KLK5 impacts ovarian cancer patients′ survival［J］. Ann Oncol, 2011, 22(8):1783-1790. ［4］ Bayani J, Diamandis EP. The physiology and pathobiology of human kallikrein related peptidase 6(KLK6)［J］. Clin Chen Lab Med, 2011, 50(2):211-233. ［5］ El Sherbini MA, Sallam MM, Shaban EA, et al. Diagnostic value of serum kallikreinrelated peptidases 6 and 10 versus CA125 in ovarian cancer［J］. Int J Gynaecol Cancer, 2011, 21(4):625-632. ［6］ Dorn J, Gkazepis A, Kotzsch M, et al. Clinical value of protein expression of kallikreinrelated peptidase 7 (KLK7) in ovarian cancer［J］. Biol Chem, 2014, 395(1):95-107. ［7］ Kountourakis P, Psyrri A, Scorilas A, et al. Expression and prognostic significance of kallikreinrelated peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis［J］. Thromb Haemost, 2009, 101(3): 541-546. ［8］文彦. 卵巢上皮性癌患者肿瘤组织和血清KLK8的表达及临床意义［J］. 大家健康(学术版), 2012, 6(9):6-8. ［9］ Yousef GM, Kyriakopeulou LG, Seorils A, et al. Quantitative expression of the human kallikrein gene 9(KLK9) in ovarian cancer：a new independent and favorable prognostic marker［J］. Cancer Res, 2001, 61(21):7811-7818. ［10］ El Sherbini MA, Sallam MM, Shaban EA, et al. Diagnostic value of serum kallikreinrelated peptidases 6 and 10 versus CA125 in ovarian cancer［J］. Int J Gynaecol Cancer, 2011, 21(4):625-632. ［11］王翠翠, 张晓霞, 王丽娜, 等. 卵巢癌患者血清人激肤释放酶10的检测及其临床意义［J］. 吉林大学学报(医学版), 2010, 36(3):540. ［12］ Borgoo CA, Fracchioli S, Yousef GM, et al. Favorable prognostic value of tissue human kallikrein 11 (hk11) in patients with ovarian carcinoma［J］. Int J Cancer, 2003, 106(4):605-610. ［13］岳军, 梅立, 谢兰. KLK11在卵巢肿瘤组织中的表达及其临床相关性［J］. 四川医学, 2013, 34(1):25-27. ［14］ White NM, Mathews M, Yousef GM, et al. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma［J］. Br J Cancer, 2009, 101(7):1107-1113. ［15］ Yousef GM, Fracchioli S, Scorilas A, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer［J］. Am J Clin Pathol, 2003, 119(3):346-355. ［16］颜秋梅, 李巧云, 闻立红. 激肽释放酶14在卵巢癌组织中的表达及临床意义［J］. 中国实用医药, 2013, 8(11):28-29. ［17］ Yousef GM, Scorilas A, Katsaros D, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer［J］. J Clin Oncol, 2003, 21(16):3119-3126. ［18］张颖, 史惠蓉. 上皮性卵巢癌组织中组织激肽释放酶15和CA125蛋白的表达［J］. 郑州大学学报(医学版), 2010(1): 62-65.

[1]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[3]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[4]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[5]	Li Chenxi, Zhao Hongwei. Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors [J]. Journal of International Oncology, 2021, 48(3): 180-183.
[6]	Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao. GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway [J]. Journal of International Oncology, 2021, 48(12): 716-722.
[7]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan. Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer [J]. Journal of International Oncology, 2021, 48(11): 660-665.
[8]	Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran. Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells [J]. Journal of International Oncology, 2020, 47(6): 333-339.
[9]	Xue Chen, Zhao Yue, Shi Guang, Tang Yan. Research progress of PD-1/PD-L1 inhibitors in ovarian cancer [J]. Journal of International Oncology, 2020, 47(5): 312-315.
[10]	Yang Yiting, Cheng Zhongping. The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer [J]. Journal of International Oncology, 2020, 47(4): 249-251.
[11]	Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan. Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance [J]. Journal of International Oncology, 2020, 47(2): 82-89.
[12]	Quan Ruiquan, Zhang Li, Kuang Li, Li Hongbo, Xiao Meixian. Efficacy of olaparib combined with bevacizumab in the treatment of patients with recurrent platinum-sensitive ovarian cancer and its effect on serum HE4, CA125 and CTC levels [J]. Journal of International Oncology, 2020, 47(10): 606-610.
[13]	Tang Nanmin, Yu Zhancai. Transforming growth factor-β signaling pathway and targeted therapy in ovarian cancer [J]. Journal of International Oncology, 2019, 46(9): 562-565.
[14]	Chu Chaonan, Huang Qi. Comparison of the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxaliplatin in the treatment of recurrent platinum resistant ovarian cancer [J]. Journal of International Oncology, 2019, 46(1): 32-35.
[15]	Yuan Qiuyue, Qiao Huimin, Zhang Shengmiao, Xia Baoguo, Bi Shuna, Chen Long. Research progress of circulating tumor DNA in ovrian cancer [J]. Journal of International Oncology, 2019, 46(1): 57-60.